As the metabolic medicine landscape evolves, questions of safety, access, complementary nutritional approaches, and realworld use will only grow sharper
The planned CAPEX is INR100 Crs in FY26 to increase medical pen (injector) capacity from ~45 million to ~85 million devices due to the forecasted demand of Ozempic and other weight loss drugs
I went from 256 lbs in August 2025 to 220 by February 2026 (paired with working out), and Im stronger than Ive been in years
Preclinical models demonstrate that region-specific elevations of central KYNA highlight a functional trade-off: while KYNA is often considered neuroprotective due to its antagonism of glutamatergic receptors, its broad receptor profile also allows it to inhibit 7nAChRs, which are essential for prefrontal cortical processing and mood regulation
In conclusion, these results accord with the previous NO-system studies [1026] and the particular BPC 157 effect on hemostasis [1,2]